Background Accumulating evidence indicates that trimethylamine-N-oxide (TMAO) may play
a causal role in cardiovascular disease (CVD), chronic kidney disease (CKD) and type 2 …

Trimethylamine N-oxide (TMAO) is a biologically active molecule and is a putative promoter
of chronic diseases including atherosclerosis in humans. Host intestinal bacteria produce its …

The gut microbiota-derived metabolite trimethylamine N-oxide (TMAO) has been regarded
as one of the potent risk factors for cardiovascular events and diabetes. In the current meta …

Trimethylamine-N-oxide (TMAO) is the main diet-induced metabolite produced by the gut
microbiota, and it is mainly eliminated through renal excretion. TMAO has been correlated …

TMAO is elevated in individuals with cardiometabolic diseases, but it is unknown whether
the metabolite is a biomarker of concern in healthy individuals. We conducted a cross …

Abstract Background Trimethylamine-N-Oxide (TMAO) is a proatherogenic and
prothrombotic metabolite. Our study examined the association of plasma TMAO level with …

Objective Our study aimed to explore the association between trimethylamine N-oxide and
frailty in older adults with cardiovascular disease. Patients and Methods This cross-sectional …

Chronic kidney disease (CKD) is strongly associated with increased cardiovascular risk.
Impaired endothelial function, a key initiating step in the pathogenesis of cardiovascular …

Background and aims Recent studies have shown that trimethylamine N-oxide (TMAO) is a
risk factor for cardiovascular disease (CVD) in different clinical settings, but few studies …

The gut microbial metabolite trimethylamine N-oxide (TMAO) is increasingly regarded as a
novel risk factor for cardiovascular events and mortality. However, little is known about the …